<DOC>
	<DOC>NCT01185184</DOC>
	<brief_summary>This study will explore the drug behavior and safety following single dose of two 20 milligram CP-690,550 osmotic capsules in 12 healthy volunteers. These will be compared to a 10 milligram immediate release tablet, using a 3 way crossover design.</brief_summary>
	<brief_title>Pharmacokinetics And Safety Study Of Two CP-690,550 Controlled Release Formulation Following Single Dose In Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Healthy male and/or female subjects Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease. Clinically significant infections within the past 3 months.</criteria>
	<gender>All</gender>
	<minimum_age>21 Months</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Relative bioavailability</keyword>
	<keyword>controlled release</keyword>
	<keyword>Phase 1</keyword>
	<keyword>CP-690</keyword>
	<keyword>550</keyword>
</DOC>